Opinion - Why is Massachusetts spending taxpayer money to demonize pregnancy help clinics?
Massachusetts Gov. Maura Healey (D) is running a massive taxpayer-funded public relations campaign to warn citizens about the dangers of pregnancy help clinics. Healy is claiming that this is necessary because people who run these clinics have 'a pro-life and religious bias.'
There are some flaws to this thinking. For one thing, approximately half the country has a pro-life bias. And a 2023 Gallup poll says that 82 percent of Americans identify as religious or spiritual.
And when it comes to helping young women facing unexpected pregnancies, politicians should avoid getting themselves on the wrong side of yet another 80/20 issue. Pregnancy help clinics are good for America, especially for politicians committed to defending legal abortion.
It is true — there is a clear and present pro-life and religious bias at work in the nearly 3,000 pregnancy help services operating across the U.S.. This same bias prompted the Rev. John Barlett (1784–1849) to found Mass General Hospital, one of the oldest hospitals in America today. He was a pro-life Christian who wanted to save lives in the name of Jesus. Was he dangerous?
Even now, there are medical professionals working at Mass General who are motivated by a love of life and a Christian worldview. Should we warn people about this?
In fact, nearly all of the hospitals and clinics in the world today that are more than 100 years old were started by people with a pro-life and religious biases. Such bias drove the medical missionary, Dr. Alexander Pearson, to leave the comforts of home and introduce the smallpox vaccine to China in 1805. By 1901, medical missionaries in China were operating 128 hospitals and 245 dispensaries. They recorded 1,674,571 people treated, out of the same bias of Christian care that motivates people to set up pregnancy help clinics and provide testing, ultrasound and practical support for expectant mothers.
I led the effort to establish ultrasound-equipped, medically-staffed pregnancy help centers in the Boston area starting in 1992. As a Baptist pastor in the Boston neighborhood of Dorchester, I heard many tearful testimonies of my people, saying, 'I regret my abortion.' As they told me of their lived experience, they also indicated what kind of help, if offered, would have saved their baby. We decided to offer this help.
We started with nothing more than neighborly love and the paradigm of the good Samaritan — draw near and provide practical help. The first to join the effort were those who had their own abortion story. Such people are not judgmental. They are sympathetic and knowledgeable, knowing the stress, the sense of panic and the unclear thinking that attends crisis.
The principle that makes any medical treatment ethical is so foundational that it is called the doctrine of informed consent. The comprehensive abortion training textbook 'A Clinician's Guide to Medical and Surgical Abortion' states that informed consent 'must include three elements.' Patients must have the capacity to make decisions; their decisions must be without coercion; and patients must be given appropriate information germane to their decision.
'The goal of the informed consent,' the textbook says, 'is to protect individual autonomy by providing information on the procedure, risks, and alternatives to the medical intervention being considered.' And it provides a list of 14 negative after-abortion reactions that must be screened for prior to abortion, including the two I heard most often, 'significant ambivalence' and 'perceived coercion.'
It is an 80/20 issue that this advice on pre-abortion screening, for negative reactions to abortion, is good for women. Even the National Abortion Federation says so — its logo is stamped right on the cover of 'The Clinician's Guide.'
Abortion advocates can be confident, even thankful, that every woman who seeks an abortion after visiting a pregnancy help center has been informed about the abortion procedures and risks, just as abortion trainers teach. If in the process a mother or couple decides, in spite of difficult circumstances, to have their baby, why not just be glad? Or at least be neutral? Their choice doesn't alter the legal status of abortion in any way.
Pregnancy help services are spreading worldwide without controversy. In China, a few public hospitals are now offering pregnancy help counseling services and support. In Vietnam, too, hospitals are experimenting with 'counseling corners' for women prior to abortion.
In hard places, like Cuba and Uganda, my organization equips doctors with a hand-held ultrasound to help young mothers see their unborn children. Volunteers help new mothers follow their hearts and their true values and give life.
Even abortion doctors welcome the services of pregnancy help clinics, if for no other reason than that they help women who are ambivalent or feeling pressured by others. One such abortion doctor in Romania told me of his deep frustration that he did not have such a clinic nearby. 'Some women are weeping and shaking when I start the process,' he said. 'I welcome you to open a [clinic] next to me. I would send these women to you to sort out.'
John Ensor is a speaker, author, and president of PassionLife.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to The Hill.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
21 minutes ago
- Fox News
Federal judge again blocks deportation of anti-Israel Columbia protester
A federal judge has blocked the Trump administration from detaining a Columbia University student and lawful permanent resident whom federal agents have targeted for deportation after she took part in an anti-Israel demonstration earlier this year. U.S. District Judge Naomi Reice Buchwald's preliminary injunction on Thursday blocks Immigration and Customs Enforcement (ICE) from taking 21-year-old Yunseo Chung into custody. Chung is originally from South Korea and has lived in the U.S. since she was seven years old. ICE had attempted to arrest her in March but were unsuccessful and the court has now barred ICE from detaining her without prior approval. If the government tries to detain Chung for any reason other than her potential deportation, it must give 72 hours' notice to Chung's lawyers and the court and allow the court time to determine if the detention attempt is a pretext for First Amendment retaliation. The ruling also states that she remains free while her legal case proceeds. Ramzi Kassem, co-director of CLEAR, a legal nonprofit at City University of New York that is representing Chung, praised the ruling. "This is a win not just for Yunseo and for the legions of people who stand up for Palestinians and oppose the daily atrocities in Gaza that our government underwrites, but also for freedom of speech and the rule of law in our country," Kassem said in a statement, per the Washington Post. It comes after the same judge in March ordered immigration officials to cease their efforts to arrest Chung. The Trump administration has alleged that her participation in a protest poses a potentially serious adverse foreign policy consequence for the United States. Chung's attorneys say that the government's pursuit of the Columbia student is an "unjustifiable assault on [the] First Amendment." Chung sued the government earlier this year. The lawsuit states that Chung was a participant in the anti-Israel protests, not a leader, and was "one of a large group of college students" expressing "shared concerns" over the war in Gaza. Chung, according to the lawsuit, "visited" the Gaza Solidarity Encampment, a number of tents organized in the center of campus, but does not state whether she stayed there. The lawsuit also makes it clear that she did not make public statements or engage in high-profile activities while at the protests. Chung's lawsuit states that she was never arrested or disciplined in relation to events at the encampment. However, she was later arrested during a 2025 protest at Barnard College. The lawsuit claims that it is common in New York City for police to arrest many protesters and that charges are usually dropped or dismissed. The lawsuit states that on March 8, an ICE official signed an administrative arrest warrant for Chung and federal law enforcement went to Chung's parents' house the next day seeking to arrest her. An ICE official allegedly told Chung's attorneys on March 10 that her green card had been "revoked," according to the lawsuit. The government has the authority to rescind permanent resident status if it believes that a person has violated U.S. immigration law. Chung's attorneys say in the lawsuit that law enforcement searched Chung's dorm room on March 13 in accordance with a warrant. She was valedictorian of her high school senior class and has a near-perfect GPA heading into her senior year, according to court documents. Chung is double-majoring in English and women's and gender studies at Columbia, the Washington Post reported. The Trump administration has also sought to deport former Columbia student Mahmoud Khalil, whom it accuses of playing a major role in anti-Israel protests at Columbia University.
CNN
21 minutes ago
- CNN
Trump tells CNN he's ‘not even thinking about Elon' and won't speak to him ‘for a while'
President Donald Trump told CNN on Friday he is 'not even thinking about' billionaire Elon Musk and won't be speaking to him in the near future. 'I'm not even thinking about Elon. He's got a problem. The poor guy's got a problem,' Trump told CNN's Dana Bash. The comments come after a day Trump and Musk traded barbs on social media as their relationship deteriorated in spectacular public fashion. Trump said Thursday he was 'very disappointed' with the tech billionaire for criticizing his massive tax and spending cuts package while Musk fired back that 'Trump would have lost the election' without him. In a brief phone call, Trump talked about the forthcoming jobs report, inflation and gas prices. Asked if he had a call with Musk, the president responded: 'No. I won't be speaking to him for a while I guess, but I wish him well.' As the two powerful onetime friends duked it out online on Thursday, their shared allies sought to quietly broker a truce, CNN previously reported. Musk, for his part, appeared open to a thaw. 'You're not wrong,' Musk responded to a post from billionaire investor Bill Ackman, who wrote on X: 'I support @realDonaldTrump and @elonmusk and they should make peace for the benefit of our great country. We are much stronger together than apart.'
Medscape
30 minutes ago
- Medscape
Which Tx Combo Is Best for HER2+ Breast Cancer?
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other interim results of the phase 3 DESTINY-Breast09 study, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. 'Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% reduction in the risk of disease progression or death when compared to a taxane, trastuzumab, and pertuzumab (THP),' said Tolaney, during her presentation. New First-line Standard? Similar results were observed across all patient subgroups, with no new safety signals, Tolaney said. 'These data suggest that T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer,' she said. The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP). The interim study readout includes only data from the T-DXd-pertuzumab and the taxane plus trastuzumab with pertuzumab groups. Pertuzumab + T-Dxd or Standard of Care? Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients ( P < .00001). Tolaney explained that the study was designed to have an interim analysis for PFS after approximately 399 events across the three arms with at least 277 events for comparison. At the time of the interim analysis, she said, only the TDX-pertuzumab and THP groups met the criteria for superiority, a P -value < .00043, which was not met for the comparison of T-DXd plus placebo to THP. The T-DXd-placebo arm remains blinded until the final progression-free survival analysis, Tolaney said. Twenty-one percent of the patients in the T-DXd-pertuzumab arm had discontinued T-DXd due to adverse events, Tolaney said; 9% of patients elected to continue with trastuzumab and pertuzumab after they discontinued T-DXd. Among hormone receptor-positive patients, 13.5% in the T-DXd-pertuzumab group and 38% in the THP group elected to add endocrine treatment. At the data cutoff, 46% of the T-DXd-pertuzumab patients and 33% of those in the THP group remained on study treatment. Median follow-up duration was 29 months. The treatment effect of T-DXd-pertuzumab became evident early in the study, Tolaney said. Six months after starting treatment, 7% of the T-DXd-pertuzumab group vs 12% of the THP group had progressed. The gap continued to widen over time, she said. 'With 26% of patients still on steady treatment with T-DXd and pertuzumab, it suggests that this median is likely to evolve with further follow-up,' she said. Objective response rates were also higher with T-DXd–pertuzumab, 86% vs 79% with THP, Tolaney said. 'The complete response rate for T-DXd and pertuzumab was 15%, which was almost double what was seen with THP (8.5%),' she said. Response duration was also longer with T-DXd-pertuzumab, with 73% remaining in response at 24 months vs 55% in the THP arm. 'Overall survival data are very immature at this timepoint with just 16% of survival events seen, but you can see that there is an early trend favoring T-DXd plus pertuzumab with a hazard ratio of 0.84,' she said. A similar number of patients in both groups had serious treatment-emergent adverse events: 27% for T-DXd-pertuzumab and 25.1% for THP, which Tolaney said, was consistent with the known toxicity profiles of both agents, with no new toxicities identified. The median duration of treatment in the DESTINY-Breast09 study was 21 months. 'A Pivotal Advancement?' Rebecca Dent, MD, deputy CEO at the National Cancer Center Singapore, called the DESTINY-Breast09 results 'a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statistically significant.' Rebecca Dent, MD HER2-positive metastatic breast cancer was once considered a 'death sentence,' Dent said at a press conference, but now patients can survive on therapy for years, which presents its own challenges. Regarding the T-DXd-plus-pertuzumab regimen, Dent said, 'Is this for all patients at the beginning of their treatment for metastatic disease?' The truth of the matter is we don't know.' Having better biomarkers would provide answers, she said, but for patients with extensive disease with central nervous system metastasis, pertuzumab in combination with other agents 'is clearly your first-line choice.' How to best sequence therapies is another challenge emerging with these evolving treatment regimens, Dent added. 'And then I think finally we do have to appreciate that there are toxicities: One in terms of quality of life but also cost toxicity,' she said. Which Therapeutic Regimen Costs More? Tolaney acknowledged the cost implications of adding pertuzumab to T-DXd, in an interview with Medscape Medical News . 'But I would also note,' Tolaney said, 'that the standard-of-care arm does involve getting continued trastuzumab and pertuzumab therapy.' In the PATINA study, which added palbociclib (Ibrance) to standard maintenance therapy in patients with HER2-positive metastatic breast cancer, the cost profile was similar to those of the treatments used in the newer trial, Tolaney said. 'You are looking at substantial continued cost because we're continuing to suppress the HER2 pathway for years in these patients,' she said. AstraZeneca and Daiichi Sankyo funded the study. Tolaney reported financial relationships with ADi, Ambrx, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Hengrui Pharmaceutical (USA), Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana, NanoString Technologies, Natera, Novartis, OncoPep, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Summit Therapeutics, Systimmune, Tango Therapeutics, Zentalis, Zuellig Pharma, and Zymeworks. Dent reported having financial relationships with AstraZeneca, Daiichi Sankyo/Astra Zeneca, DKSH, Eisai, Gilead Sciences, Merck Sharpe and Dohme, Novartis, Pfizer, and Roche.
